Release date: 27 September 2010
Promoter – Financial Intermediary
Pharmathen S.A.
Location
Description
The project concerns the promoter’s R&D activities from 2010 to 2013, related to the development of Active Pharmaceutical Ingredients (API) for generic pharmaceuticals, including new manufacturing processes.
Objectives
The project objectives are to enlarge the company’s generic product offering and develop new drug delivery techniques for originator drugs approaching patent expiry, with the aim of extending protection from generic competition through life-cycle management. Apart from research and development, the project also comprises regulatory approval processes.
Comments
Loan foreseen under the Risk Sharing Finance Facility (RSFF).
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 25 million.
Total cost (Approximate amount)
The promoter’s budgeted R&D expenses for the years 2010-2013, i.e. the project costs, are about EUR 55 million.
Environmental aspects
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres etc. Thus an Environmental Impact Assessment (EIA) according to the EU Directive 97/11, as amended by Directive 2003/35, is not required.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 17/12/2010
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).